Lymphoma Trial, Recruiting (NCT07203742)

Lymphoma Trial, Recruiting NCT07203742 Sponsor: Ege University Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT07203742 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children between 4 and 12 years of age
Children who are currently in hospital and being cared for at a Pediatric Hematology Clinic
Children who are receiving treatment for leukemia only
Children who do not have any other long-term or ongoing health conditions
Children who do not have any active widespread infection in the body
Children who have already completed at least two rounds of chemotherapy delivered directly into the fluid around the spine
Children who have not been diagnosed with any psychological or mental health symptoms as a side effect of their chemotherapy
Children who are scheduled to receive further chemotherapy delivered into the fluid around the spine as part of their treatment plan
Both the child and their parent or caregiver must be willing to take part voluntarily
The parent or caregiver looking after the child must speak Turkish and be able to communicate openly with the study team

Who may not be able to join:

Children and families who do not meet all of the criteria listed above would not be eligible to take part in this study (confirm with trial site for specific details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Seda Ardahan Sevgili, Ph.D., Ege University

Phone: 00902323115572

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07203742

Sponsor: Ege University

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: 00902323115572

More information: https://clinicaltrials.gov/study/NCT07203742

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children between 4 and 12 years of age
Children who are currently in hospital and being cared for at a Pediatric Hematology Clinic
Children who are receiving treatment for leukemia only
Children who do not have any other long-term or ongoing health conditions
Children who do not have any active widespread infection in the body
Children who have already completed at least two rounds of chemotherapy delivered directly into the fluid around the spine
Children who have not been diagnosed with any psychological or mental health symptoms as a side effect of their chemotherapy
Children who are scheduled to receive further chemotherapy delivered into the fluid around the spine as part of their treatment plan
Both the child and their parent or caregiver must be willing to take part voluntarily
The parent or caregiver looking after the child must speak Turkish and be able to communicate openly with the study team

Who may not be able to join:

Children and families who do not meet all of the criteria listed above would not be eligible to take part in this study (confirm with trial site for specific details)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ege University

Registry

ClinicalTrials.gov

Start date

29 September 2025

Est. completion

1 August 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Fear of intrathecal chemotherapy; Anxiety of intrathecal chemotherapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov